INTRODUCTION
Reversible protein phosphorylation of serine or threonine residues preceding a proline (pSer/Thr-Pro) is a central signaling mechanism in diverse cellular processes in physiology and disease (Blume-Jensen and Hunter, 2001; Lu et al., 2002; Nigg, 2001) . Notably, certain pSer/Thr-Pro motifs in phosphopeptides exist in two distinct cis and trans conformations (Yaffe et al., 1997) , and their isomerization is especially important because Pro-directed kinases and phosphatases are cis or trans conformation specific (Brown et al., 1999; Zhou et al., 2000) . Moreover, phosphorylation slows down their isomerization rate and renders the peptide bond resistant to conventional peptidyl-prolyl cis-trans isomerases (PPIases) (Yaffe et al., 1997; Zhou et al., 2000) . However, the PPIase Pin1 (Lu et al., 1996) binds to and isomerizes specific pSer/Thr-Pro motifs in a subset of proteins, leading us to hypothesize that Pin1 catalytically regulates its substrate conformation after phosphorylation to control protein function (Lu et al., 1999a (Lu et al., , 1999b Ranganathan et al., 1997; Shen et al., 1998; Yaffe et al., 1997; Zhou et al., 1999 Zhou et al., , 2000 .
Subsequent studies have provided supporting evidence for postphosphorylation conformational regulation (Liou et al., 2011; Lu and Zhou, 2007) . For example, Pin1 greatly accelerates isomerization of the APP intracellular domain between the two distinct conformations, as visualized by nuclear magnetic resonance (NMR) (Pastorino et al., 2006) and has profound effects on a spectrum of activities of numerous signaling molecules (Girardini et al., 2011; Liou et al., 2011; Lu and Zhou, 2007; Theuerkorn et al., 2011; Tun-Kyi et al., 2011; Yuan et al., 2011) . Functionally, Pin1 regulates many cellular processes involving Pro-directed phosphorylation, with an emerging theme that Pin1 often acts on multiple targets to synergistically drive certain cellular processes to a single direction (Liou et al., 2011; Lu and Zhou, 2007) . Importantly, Pin1 deregulation contributes to an increasing number of diseases, notably cancer and Alzheimer's disease (AD) (Butterfield et al., 2006; Lee et al., 2011b; Lu and Zhou, 2007) . These Pin1 functions are abolished by catalytically inactivating mutations (Lu and Zhou, 2007) or DAPK1-mediated inhibitory phosphorylation (Lee et al., 2011a) . However, without a tool to detect cis-or trans-specific protein conformation in the cell, there is no direct evidence for protein cis-trans isomerization in vivo, or for isomer-specific regulation of function (Liou et al., 2011; Lu and Zhou, 2007) .
The neuropathological hallmarks of AD are tangles made of hyperphosphorylated tau (p-tau) and plaques composed of amyloid beta-peptides (Ab) derived from amyloid precursor protein (APP) (Ballatore et al., 2007; Goedert and Spillantini, 2006; Mattson, 2004; Spires-Jones et al., 2009) . It is increasingly evident that tau pathology in AD may result from the combination of the detrimental effects of loss of normal tau function to promote microtubule (MT) assembly and toxic gain of function acquired by p-tau aggregates (Ballatore et al., 2007) . A defining early event that disrupts tau MT function and precedes tangle formation and neurodegeneration in AD is increased tau phosphorylation, especially on Ser/Thr-Pro motifs (Ballatore et al., 2007; Goedert and Spillantini, 2006; Mattson, 2004; Spires-Jones et al., 2009) . Many kinases or phosphatases are deregulated in AD brains, and modulating these enzymes can affect AD-related phenotypes (Ballatore et al., 2007; Cruz and Tsai, 2004; Dolan and Johnson, 2010) . However, it is not clear how such phosphorylation becomes pathogenic, or how to control it.
Recently, we have found a pivotal role for Pin1 in protecting against age-dependent neurodegeneration in AD (Lee et al., 2011b) . Pin1 binds to and isomerizes the pThr231-Pro motif in tau and the pThr668-Pro motif in APP in vitro (Lu et al., 1999a; Pastorino et al., 2006; Zhou et al., 2000) . Furthermore, Pin1 restores p-tau regulation of MTs, and also promotes p-tau dephosphorylation and degradation (Lim et al., 2008; Liou et al., 2003; Lu et al., 1999a; Zhou et al., 2000) . Pin1 also reduces amyloidogenic APP processing and toxic Ab secretion (Pastorino et al., 2006) , and promotes p-APP degradation (Ma et al., 2012a) . Consequently, Pin1 knockout mice develop age-dependent tauand Ab pathologies, and neurodegeneration, resembling many aspects of human AD (Liou et al., 2003; Pastorino et al., 2006) . By contrast, Pin1 overexpression in postnatal neurons effectively inhibits tau pathology and neurodegeneration in AD mouse models overexpressing human wild-type tau (Lim et al., 2008) . Significantly in human brains, Pin1 is highly expressed in most neurons but is inhibited in mild cognitive impairment (MCI) and AD neurons (Butterfield et al., 2006; Liou et al., 2003; Lu et al., 1999a) , whereas a Pin1 single-nucleotide polymorphism (SNP) that prevents its downregulation is associated with delayed onset of AD (Ma et al., 2012b) . Notably, Thr231 phosphorylation is the first of a sequential cascade of phosphoepitopes that appear during pretangle formation in AD (Luna-Muñ oz et al., 2007) . Thus, Pin1 might accelerate cis-to-trans isomerization to protect against tau and Ab pathology in AD Lu and Zhou, 2007) . However, there is no evidence that Pin1 actually regulates protein conformation in vivo in AD or in any other process.
To detect Pin1-catalyzed conformational changes, we have developed peptide chemistries suitable for the generation of antibodies that can distinguish cis from trans pThr231-Pro conformation in p-tau. We provide direct evidence that Pin1 accelerates cis-to-trans conversion, preventing pathogenic cis p-tau accumulation and tau pathology in AD.
RESULTS
Generation of cis and trans Conformation-Specific Antibodies Proline-directed phosphorylation is a central signaling mechanism in the cell, but it is unknown whether such a phosphoprotein exists in cis and trans conformations in vivo. To address this question, we developed a strategy to generate antibodies that can distinguish cis from trans pThr231-Pro conformation in p-tau. NMR analysis showed that only 9% of a synthetic tau peptide containing the pThr231-Pro motif exists in the cis conformation ( Figure 1A ; Figure S1A available online), making it difficult to produce cis-specific antibodies. Therefore, we immunized rabbits with a modified pThr231-Pro tau peptide that contains a minimal structural change but has both cis and trans contents high enough to produce cis-and trans-specific antibodies, followed by separation using affinity purification and counterpurification procedures to remove potential contamination with cis-and trans-locked peptides, respectively ( Figure 1B) .
Because the five-membered carbonyl ring of proline allows its peptide bonds to adopt cis and trans conformations, we reasoned that replacing this ring with a six-membered ring containing one additional methylene group, as seen in homoproline (Pip), might increase the cis content and allow the generation of antibodies that would recognize endogenous tau isomers. To test this hypothesis, we used NMR analysis to determine the cis and trans contents of modified tau peptides. Indeed, a pThr231-Pip tau peptide contained 74% cis peptide (Figures 1A, S1A, and S1B). When immunizing rabbits, the pThr231-Pip tau peptide produced antibodies that recognize endogenous human and mouse tau ( Figures 1E-1H ). To separate cis-and trans-specific antibodies, we synthesized a pThr231-Dmp (5,5-dimethylproline) tau peptide as a cis-locked peptide because Dmp locks a peptidyl-prolyl bond in cis , and a pThr231-Ala tau peptide as a pure trans peptide because Ala adopts only the trans conformation, as confirmed by NMR ( Figures 1A, S1C , and S1D).
After the antibody purification outlined in Figure 1B , the specificity of resulting cis-and trans-specific antibodies was first verified using ELISA. Both cis ( Figure 1C ) and trans ( Figure 1D ) antibodies specifically recognized their respective cis and trans peptides, with essentially no cross-reactivity. Their calculated K d values for the respective cis and trans pT231-tau peptides were 2.1 and 1.6 nM. Importantly, they did not recognize an unphosphorylated Thr231-Pro tau peptide, but both were strongly reactive to a wild-type pThr231-Pro tau peptide, as expected from the fact that cis and trans isomers in phosphopeptides can be interchanged relatively easily (Pastorino et al., 2006; Zhou et al., 2000) . Thus, cis and trans pThr231-Pro tau antibodies are highly conformation specific in vitro.
Next, to examine whether the cis and trans antibodies recognize pThr231 in tau in vivo, we performed immunoblotting and immunostaining analyses. When tau and its T231A mutant were expressed in neuronal SY5Y cells, both antibodies recognized wild-type tau but not its T231A mutant ( Figure 1E ), similar to ELISA results ( Figures 1C and 1D) . Furthermore, robust cis and trans immunostaining signals were detected in tau transgenic (Tau-Tg) mouse brains overexpressing wild-type human tau, but not after dephosphorylation (Lu et al., 1999a) or in tau knockout mouse brains ( Figure 1F ). When frontal cortical sections from advanced AD patients were double immunostained with the cis or trans polyclonal antibody and a monoclonal antibody recognizing total tau, all cis-or trans-positive neurons were also positive for total tau, but not all total tau-positive neurons were also positive for either cis or trans p-tau (Figure 1G ), indicating that some, but not all, of tau is phosphorylated on Thr231, as expected. In addition, immunostaining signals of both cis and trans pThr231-Pro antibodies in AD brains partially colocalized with those of AT180 ( Figure S1E ) and TG3 (Figure S1F) , two antibodies recognizing pT231-containing tau See also Figure S1 . (Jicha et al., 1997) . Thus, cis and trans antibodies recognize pT231-containing tau (pT231-tau) in vivo. Finally to determine whether these immunostaining signals are specific to cis or trans pT231-tau, we preabsorbed the antibody with cis, trans, or cis + trans pT231-tau peptide prior to immunostaining of AD frontal cortex. Staining signals of the cis antibody were abolished by preabsorption with the cis, but not trans peptide and vice versa ( Figure 1H ). Of note, a monoclonal antibody that recognized only the cis pThr231-Dmp tau peptide, but not pThr231-Pro tau peptide in ELISA ( Figure S1G ) could not generate any immunostaining signal in Tau-Tg mouse brains ( Figure S1H ). Thus, cis and trans pT231-tau antibodies are conformation and phosphorylation specific in vitro and in vivo.
cis, but Not trans, pT231-Tau Is a Very Early Conformation Associated with AD Progression In human AD, Thr231 phosphorylation is the first detectable tau phosphorylation event (Luna-Muñ oz et al., 2007) , and its levels track disease progress (Ewers et al., 2007; Hampel et al., 2001) . However, it is not known whether cis, trans, or both pT231-tau conformations are elevated. Moreover, the involvement of pT231-tau isomerization in MCI has not been tested. Generation of the cis-and trans-specific antibodies provides an opportunity to address these questions.
Immunostaining of human frontal cortical sections revealed that tau protein was readily detected in normal neurons and total amounts were increased with progression of neurodegeneration, especially in AD brains ( Figure 2A ). Although very little, if any, cis or trans pT231-tau signals were detected in 9 normal brains, cis pT231-tau signals were dramatically increased in 11 AD brains ( Figure 2A ). Strong cis, but not trans, pT231-tau was detected in 4 out of 6 MCI cases ( Figure 2A ), with weaker but clearly detectable cis signals in remaining 2 MCI cases (data not shown).
To confirm the above results, we performed immunoblotting analysis of frontal cortical lysates obtained from 9 normal controls with Braak stages I and II, 6 MCI patients with Braak stages III and IV, and 11 AD patients with Braak stage V and VI to semiquantify their cis and trans pT231-tau contents. We used cis and trans p-tau in tau-overexpressing SY5Y neuronal cells as relative standards for comparison. Again, although neither cis nor trans was detected in normal brains ( Figure 2B ), cis pT231-tau was elevated in MCI brains and further accumulated as the Braak stage progresses, with much smaller increases in trans p-tau ( Figures 2C and 2D ). These results suggest that cis pT231-tau is specifically elevated in MCI and AD brains. Both cis and trans signals were detected by immunoblotting under denatured and native conditions ( Figure S2A ). The ability to detect cis and trans pT231-tau conformations by immunostaining and immunoblotting is perhaps surprising given the disruptive nature of these techniques. However, many antibodies raised against human AD paired helical filaments recognize AD-specific abnormal p-tau conformations in immunostaining and immunoblotting, suggesting that these conformations are in fact rather stable (Davies, 2000) .
The above results suggest that cis pT231-tau might be more pathologically relevant, and this is further supported by the strikingly different subcellular localizations of cis and trans p-tau in MCI and AD brains. Although both p-tau conformations were found in neuron bodies in the frontal cortex, only cis pT231-tau was detected in neurites of MCI and AD brains, with more and more being accumulated in dystrophic neurites as the Braak stage increased ( Figures 1G, 2A , and S1F, yellow arrows). Notably, p-tau in dystrophic neurites was also recognized by the pT231 antibody AT180 ( Figure S2B ) and the total tau antibody DC25 ( Figure S2C ), with cis and AT180 signals being colocalized in the neurites ( Figures S1E and S2C ). In sharp contrast, there was almost no or very little trans pT231-tau in dystrophic neurites even in advanced AD brains ( Figures 1G, 2A , and S1F, blue arrows). Similar results were also confirmed using antibodies raised in a different rabbit ( Figure S1I ). This different localization pattern is likely pathologically significant given that missorting of p-tau to neurites and synaptic loss in the frontal cortex are early hallmarks of AD and are highly correlated with cognitive loss in AD patients (Davies et al., 1987; DeKosky and Scheff, 1990; Scheff et al., 1990 ). These results not only confirm the specificity of the cis and trans antibodies but also indicate that only cis, but not trans, pT231-tau localizes to pathologically relevant dystrophic neurites.
Pin1 Restores the Ability of cis pT231-Tau to Promote Microtubule Assembly
The above results suggest that cis, but not trans, pT231-tau might be pathologically more relevant to MCI and AD. We wondered whether cis and trans p-tau conformations might have any differences in biological functions or biochemical properties relevant to tau pathology in AD, and whether they might be regulated. Pin1 is the only enzyme known to isomerize the pThr231-Pro motif in a tau peptide (Zhou et al., 2000) , to restore the ability of pT231-tau to promote MT assembly (Lu et al., 1999a) and to promote pT231-tau dephosphorylation and degradation (Lim et al., 2008; Liou et al., 2003; Lu et al., 1999a; Zhou et al., 2000) . Pin1 is inhibited by multiple mechanisms in human MCI and AD neurons (Lee et al., 2011b) . Indeed, Pin1 levels are much lower in AD brains (Figures S3A and S3B) and in MAP2-positive AD neurons ( Figure S3C ), suggesting that lower Pin1 is unlikely due to cell death. Thus, Pin1 might protect against tau pathology in AD by preventing the accumulation of the pathogenic cis p-tau.
To examine this possibility, we first examined whether Pin1 would increase cis-to-trans isomerization of pT231-tau in vitro. Both cis and trans pThr231-Pro signals were detected in tau but not its T231A mutant after phosphorylation ( Figures 3A-3C ). Importantly, adding Pin1 significantly increased trans but reduced cis pT231-tau content. In this assay, there may be two distinct functions embodied in Pin1: acceleration of cis-totrans isomerization of the pThr231-Pro motif by the PPIase domain (Pastorino et al., 2006; Yaffe et al., 1997; Zhou et al., 2000) and trans-specific binding of the pThr231-Pro motif to the WW domain (Wintjens et al., 2001) . When Pin1 was added, free trans would bind to the WW domain, depleting free trans. The PPIase would greatly accelerate cis-to-trans isomerization to maintain their equilibrium. The overall effect of Pin1 is therefore to increase the total amount of trans relative to cis. Consistent with this notion, WW domain mutant W34A Pin1 and PPIase domain mutant K63A Pin1 did not change the content of cis or trans ( Figure S3D ). Thus, Pin1 catalyzes cis-to-trans isomerization of pT231-tau in vitro.
We next examined whether such Pin1-catalyzed cis-to-trans isomerization would affect the ability of p-tau to promote MT assembly, a major tau function that is lost in AD (Ballatore et al., 2007) , using FITC-labeled tubulin, as described (Lu et al., 1999a; Nakamura et al., 2001) . As expected, MT assembly was greatly increased by tau, but not Cdc2 phosphorylated tau, which was restored by PP2A ( Figures 3D and 3G) . Furthermore, Pin1 effectively restored the ability of p-tau to promote MT assembly ( Figures 3D and 3G ). In contrast, Cdc2-treated T231A tau could still promote MT assembly and its ability to affect MT function was not affected by Pin1 ( Figures 3E and  3H ), indicating the essential role of T231 phosphorylation for Pin1 to regulate p-tau. These results confirm the previous findings that phosphorylation of tau on Thr231 by Cdc2 disrupts its ability to promote MT assembly (Lu et al., 1999a) , that Pin1 restores this function, (Lu et al., 1999a) , and that the ability of Pin1 to regulate MT function depends on T231 phosphorylation (Lim et al., 2008; Zhou et al., 2000) . More importantly, the ability (A) There is little, if any, cis or trans pT231-tau signal in age-matched normal brains, but both are dramatically increased in AD brains (especially the cis form). Strong cis, but not trans, pT231-tau was detected in MCI cases. Note that many dystrophic neurites (yellow arrows) are labeled with the cis, but not the trans, which is almost exclusively located in neuronal cell bodies (blue arrows). Scale bars represent 20 mm. (B-D) The cis form is much more abundant than the trans, especially in MCI. Frontal cortex lysates from AD and age-matched normal control (B), Braak stages III and IV (MCI), and Braak stages V and VI (AD) (C) were subjected to immunoblotting analysis with cis and trans antibodies, with short and long exposures being shown in top and bottom panels, respectively. Intensities of cis or trans signals of tau-overexpressed SY5Y cells and human brain tissues at each Braak stage were semi-quantified, and the percentages of the signals of human samples relative to that of SY5Y cells were expressed as means ± SEM (D). See also Figure S2 .
of Pin1 to restore p-tau MT assembly function was fully blocked by incubation of Pin1-treated p-tau with trans antibody, but not cis antibody (Figures 3F and 3I ). This effect of the trans antibody was dependent on Pin1 action because application of trans or cis antibody to p-tau without Pin1 did not affect MT assembly (Figure S3E) . Thus, cis, but not trans, p-tau loses the ability to promote MT assembly and Pin1 catalyzes cis-to-trans isomerization to restore this function. cis pT231-Tau Is More Stable and More Prone to Aggregation than trans pT231-Tau In addition to loss of normal tau function, p-tau in AD is more resistant to dephosphorylation and degradation and more prone to protein aggregation, resulting in toxic gains of function (Ballatore et al., 2007) . PP2A is a major Pro-directed Ser/Thr phosphatase in brain lysates that preferentially dephosphorylates pSer/Thr-Pro motifs in trans in synthetic pT231-tau peptides, as shown using chymotrypsin to chemically remove the trans conformation (Zhou et al., 2000) . To directly examine whether cis pT231-tau is specifically resistant to dephosphorylation by PP2A, we used the conformation-specific antibodies. trans, (D-I) trans, but not cis, pT231-tau promotes MT assembly. FITC-labeled tubulin was treated with wild-type or T231A mutant tau, p-tau, p-tau+PP2A, or p-tau+Pin1, followed by MT assembly assay and visualization using confocal microscopy (D and E). Addition of Pin1 or PP2A restored the ability of p-tau to promote MT assembly (D and G). The ability of T231A-p-tau to promote MT assembly was not affected by Pin1 addition (E and H). Incubation of Pin1-treated p-tau with the trans, but not cis antibody blocks MT assembly (F and I). Microtubule assembly of each treatment relative to that of p-tau (G and H) and p-tau+Pin1 (I) was quantified.
Error bars indicate mean ± SEM. See also Figure S3 .
but not cis, pThr231-Pro tau peptide was readily dephosphorylated by PP2A ( Figure 4A ), but they both were rapidly dephosphorylated by CIP ( Figure 4B ), a calf intestinal alkaline phosphatase that has no conformation specificity toward its substrates (Zhou et al., 2000) . Moreover, cis-locked pThr231-Dmp tau peptide was much more resistant to dephosphorylation by PP2A than trans pThr231-Pro tau peptide ( Figure S4A ), although it was robustly dephosphorylated by CIP ( Figure S4B ). These results provide further evidence that PP2A is a Prodirected phosphatase preferentially dephosphorylating pSer/Thr-Pro motifs in trans (Zhou et al., 2000) . Because Thr231 phosphorylation increases tau protein stability and aggregation (Lim et al., 2008) , we next compared protein stability of cis and trans pT231-tau in neuronal cells and mouse brains using a cycloheximide chase (Lim et al., 2008) . cis p-tau was much more stable than the trans; after 12 hr, cis p-tau was not reduced, whereas trans p-tau was reduced by 75% ( Figures 4C and 4D) . Given the ability of Pin1 to increase trans but decrease cis p-tau protein ( Figures  3A and 3C ), we might expect that Pin1 knockdown would increase cis, but decrease trans p-tau levels, as well as further increase cis p-tau stability. Indeed, at time 0, cis increased, but trans decreased in Pin1 knockdown cells, as compared to control cells ( Figures 4C and 4D) . Furthermore, cis was significantly more stable and had a longer half-life than trans in Pin1 KD SY5Y cells compared with control cells (Figures 4C and  4D ). Essentially the same results were obtained when inhibitors of CDKs, JNKs, and GSK-3, which are implicated in phosphorylation of tau on Thr231, were added together with CHX to assess preexisting p-tau ( Figure S4C ). In brain slice cultures from TauTg mice, cis p-tau had a longer half-life than the trans, being 24 versus 6 hr ( Figures 4E and 4F) . Thus, cis p-tau is more stable than the trans in vitro and in vivo, and Pin1 converts cis to trans to promote p-tau turnover.
To examine the effects of p-tau conformations on its aggregation, we compared the contents of cis and trans pT231-tau in sarcosyl-soluble and -insoluble fractions. In Tau-Tg mouse brains, trans p-tau was almost all in the soluble fraction, with very little, if any insoluble trans (Figures 4G and 4H) . However, cis p-tau was found almost equally between the insoluble and soluble fractions ( Figures 4G and 4H) . Similar results were also obtained in human MCI brains. As compared with trans p-tau, the cis was found much more in the insoluble fraction than in the soluble fraction for total p-tau and cleaved p-tau (de Calignon et al., Figures 4I-4L ), indicating that cis p-tau is more prone to protein aggregation.
2010) (
The above results suggest that cis pT231-tau in Tau-Tg mouse brains and human AD brains might be stable under denaturing conditions. Indeed, cis pT231-tau in the insoluble fraction of Tau-Tg mouse brains was recognized by cis, but not trans, antibody in immunoblotting independently of whether the samples were treated with SDS and boiled ( Figure S4D ). Furthermore, when we used cis antibody to immunoprecipitate cis pT231-tau from the insoluble fraction of AD brains, cis pT231-tau exhibited a range of molecular weights bigger than IgG (Figures S4E and S4F) , and was detected only by cis and total tau antibodies, but not by trans antibody ( Figure S4F ). Thus, cis p-tau is more resistant to dephosphorylation and degradation and more prone to aggregation than the trans isomer.
cis, but Not trans, pT231-Tau Correlates with Neurofibrillary Degeneration in the AD Hippocampus The above results indicate that cis, but not trans, pT231-tau not only localizes to the pathologically relevant subcellular location but also displays both losses of tau normal function as well as gains of toxic function. A critical question is whether Pin1 regulates the isomerization of pT231-tau in neurons in vivo.
To address this question, we started with investigating the relationship between Pin1 levels and cis or trans pT231-tau levels in subregions of the AD hippocampus. As shown (Liou et al., 2003) , we found that Pin1 was highly expressed in the CA2 region but was dramatically reduced in the CA1 region ( Figures 5A-5C and S5A) . Furthermore, neurons that were positive for PHF-1, a marker of neurofibrillary neurodegeneration in AD, were prevalent in the CA1 but not CA2 region ( Figures 5F,   5H , S5B, and S5C), as documented (Liou et al., 2003) . Importantly, in the CA2 region where Pin1 was highly expressed, trans-positive neurons were dominant and only few cis-positive neurons were detected ( Figures 5A, 5D , and S5A). However, in the CA1 region where Pin1 was barely expressed, cis-positive neurons were greatly increased with the number similar to that of trans-positive neurons ( Figures 5B, 5E , and S5A). The Pin1-catalyzed cis-trans conversion in vivo is likely because both cis and trans forms were present in the same neurons, as demonstrated by immunostaining of two mirror sections of the AD hippocampus with cis or trans antibody and total tau antibody as a common indicator ( Figure S5D ).
More importantly, almost all cis-positive cells were also positive for PHF-1 in both CA2 (Figures 5F and 5G ) and CA1 regions ( Figures 5H and 5I) . However, 74% of trans-positive cells in the CA2 region were negative for PHF-1 (Figures 5F and 5G) , with only 26% trans-positive cells being positive, which might be expected because Thr231 is unlikely to be the only phosphorylation site that contributes to neurofibrillary neurodegeneration in AD. Thus, cis, but not trans, pT231-tau is fully overlapped with neurofibrillary degeneration and also correlated with reduced Pin1 levels in the AD hippocampus.
Pin1 Promotes cis-to-trans Isomerization of pT231-Tau in AD Mouse Models
The above results suggest that Pin1 might prevent the accumulation of the pathogenic cis pT231-tau in the brain. To directly test the possibility, we examined the effects of Pin1 overexpression in postnatal neurons on the cis and trans contents of pT231-tau by crossing Thy1-Pin1 transgenic (Pin1-Tg) mice with Tau-Tg mice (Ishihara et al., 1999; Lim et al., 2008) . Indeed, Pin1 overexpression significantly increased trans pT231-tau but reduced cis pT231-tau, when compared with littermates that only overexpressed tau, as normalized using total tau (tau5 antibody) ( Figures 6A and 6B ) or total protein (tubulin antibody) ( Figure S6A ). These results were further confirmed by immunostaining of the cerebral cortex ( Figures 6C and 6D ). Thus Pin1 overexpression reduces cis but increases trans pT231-tau levels in mouse brains, consistent with its ability to increase cis-totrans conversion in vitro ( Figures 3A and 3C ) and to suppress neurofibrillary neurodegeneration in mice (Lim et al., 2008) .
To finally determine whether endogenous Pin1 is a ratelimiting factor that controls the levels of cis and trans pT231-tau conformations in vivo, we determined the effects of Pin1 knockout on cis and trans contents of pT231-tau by crossing Pin1 knockout mice with Tau-Tg mice. Both immunoblotting ( Figures 6E, 6F , and S6B) and immunostaining (Figures 6G and 6H) analyses showed that loss of Pin1 function significantly increased cis pT231-tau but decreased trans pT231-tau in brains. These results are consistent with the ability of Pin1 knockout to induce tau pathology and neurodegeneration (Liou et al., 2003) , in contrast to the effect of Pin1 overexpression (Lim et al., 2008) . These results were also confirmed in a condition where the intensities of the cis and trans signals are almost identical between different Tau-Tg mouse groups ( Figure S6C ). These results together indicate that cis, but not trans, pT231-tau is the pathogenic conformation in MCI and AD but is converted by Pin1 to the nonpathological trans, providing in vivo structural evidence for how the isomerase Pin1 protects against AD tau pathology.
DISCUSSION
Pin1-catalyzed cis-trans isomerization of pSer/Thr-Pro motifs is proposed to regulate many physiological and pathological processes, but there is no direct evidence for this function in vivo. We have developed a technology to generate cis-and transspecific antibodies, providing evidence that cis, but not trans, pT231-tau is pathogenic in MCI and AD and that Pin1 protects against tau pathology by converting it to the nontoxic trans form. These results provide a tool to study cis-trans prolyl isomerization and their conformation-specific function and regulation and suggest novel conformation-specific diagnoses and therapies for AD and other diseases.
Conformation-Specific Antibodies as a Tool to Study cis-trans Prolyl Isomerization
Emerging evidence suggests that both phosphorylation-dependent and -independent cis-trans prolyl isomerization functions as a molecular timer in many biological and pathological processes Theuerkorn et al., 2011) . Most of these studies are based on structural analyses in vitro, in combination with mutational analyses in cells. Until now, probably the most direct evidence for cis-and trans-specific function of a protein involved the replacement of the key Pro8 in the 5-HT 3 receptor with an unnatural Pro analog having varying cis or trans preference. This was then assayed for 5-HT 3 -dependent activity in Xenopus oocytes, leading the conclusion that cis-trans isomerization switches the channel on or off (Lummis et al., 2005) . However, the functions of endogenous cis and trans proteins still remain to be determined.
To apply the above approach to study conformational regulation after phosphorylation would be challenging, if not impossible, because such Pro analog motifs are unlikely to be phosphorylated in vivo to become Pin1 substrates (Brown et al., 1999) . To detect Pin1-catalyzed protein conformational changes, we reasoned that antibodies would only recognize either cis or trans but not both isomers of a pSer/Thr-Pro motif in a protein. This hypothesis was based on the completely distinct structures of the two isomers of pThr688-Pro-containing APP peptides revealed by NMR (Pastorino et al., 2006) .
A key step to develop such conformation-and phosphospecific antibodies is to increase the cis content of pSer/ThrPro motifs in the antigen with the smallest change possible because 90% of pSer/Thr-Pro motifs in a synthetic peptide are in trans . We have here discovered that simply increasing the Pro ring by one methylene group in a pT231-tau peptide is sufficient to dramatically increase the cis content to 74% and, importantly, to generate phospho-specific antibodies that recognize endogenous phosphoproteins. Moreover, we have developed cis-or trans-locked peptides to purify cis-and trans-specific antibodies. The resulting antibodies are highly specific, with little cross-reactivity. We have since used this technology to successfully generate isomer-specific antibodies against several other proteins (data not shown), and we believe that this approach can be widely used to study cis-and transspecific function and regulation of peptidyl-prolyl bonds, including nonphosphorylated targets.
Conformation-Specific Localization, Biological Function, and Pathological Significance in AD We have uncovered striking differences in the subcellular localization, biological function, and pathological significance of cis and trans p-tau conformations in AD (Figure 7) . Although neither cis nor trans pT231-tau is detected in the healthy brain, cis, but not trans, p-tau appears early in MCI neurons and further accumulates as AD progresses. Furthermore, cis, but not trans, p-tau is fully associated with neurofibrillary degeneration and also localizes to pathologically relevant dystrophic neurites in AD brains. Moreover, cis, but not trans, p-tau not only loses tau normal function but also gains tau toxic function, two major properties that are known to contribute to tau pathology in AD (Ballatore et al., 2007) . These results indicate that cis, but not trans, p-T231-tau is pathogenic in AD.
cis-to-trans Isomerization Prevents Pathogenic p-Tau Accumulation in AD
We have provided in vivo evidence that Pin1 protects against tau pathology by converting pathogenic cis p-tau to the nonpathogenic trans form (Figure 7) . These results provide a molecular explanation for why Pin1 overexpression promotes tau dephosphorylation and degradation and inhibits tau aggregation and tau pathology, whereas Pin1 knockout has the opposite effects in model systems (Hamdane et al., 2006; Lim et al., 2008; Liou et al., 2003) . These results are highly relevant to human AD because Pin1 is inhibited in MCI and AD neurons by multiple mechanisms (Lee et al., 2011b) , and preventing Pin1 inhibition is associated with delayed AD onset (Ma et al., 2012b) . Furthermore, Pin1 is phosphorylated and catalytically inactivated by DAPK1 (Lee et al., 2011a) , which is genetically linked to human AD and whose deletion improves learning and memory in mice (Yukawa et al., 2006) . Thus, lack of sufficient Pin1 to convert cis to trans contributes to pathogenic p-tau accumulation and tau aggregation, eventually leading to tangle formation and neurodegeneration in AD.
cis and trans Conformation-Specific Disease Diagnoses and Therapies Our findings suggest potential new approaches for early diagnosis and treatment of AD (Figure 7 ). For example, Thr231 phosphorylation is the first detectable phosphorylation event in human AD (Luna-Muñ oz et al., 2007) , and its levels in cerebrospinal fluids tracks AD progression, but with large individual variations, limiting its suitability as a standardized test (Ewers et al., 2007; Hampel et al., 2001) . Our findings that cis, but not trans, pT231-tau appears early in MCI and is pathogenic suggest that cis pT231-tau and its ratio with trans might be a better and more easily standardized biomarker, especially for early diagnosis and patient comparison. Overexpressing Pin1 or preventing Pin1 inhibition in neurons might be a valid approach to prevent tau pathology during the earliest stages of AD by reducing the cis-to-trans pT231-tau ratio. Finally, active or passive immunization against some pSer/Thr-Pro motifs in tau including the pThr231-Pro motif can reduce tau aggregates and memory deficits in mouse models (Boimel et al., 2010; Boutajangout et al., 2010 Boutajangout et al., , 2011 . However, our findings that cis, but not trans, pT231-tau is pathogenic and 90% of regular synthetic pT231-tau peptides exist in the trans conformation suggests that it might be more effective to develop conformation-specific vaccines or antibodies specifically targeting cis pT231-tau for treating or even preventing AD during its early stages. Given the critical role of Pin1 and other isomerases in regulating many other proteins in physiology and disease (Lee et al., 2011b; Liou et al., 2011; Theuerkorn et al., 2011) , it will be interesting to determine whether prolyl isomerization also regulates these protein conformations and whether such conformational switches might be exploited for developing novel diagnostic and therapeutic procedures.
EXPERIMENTAL PROCEDURES

Synthesis of Tau Peptides
Peptides used for the experiments are wild-type phosphorylated Thr231-Pro tau (KVAVVRpTPPKSPS), nonphosphorylated Thr231 tau (KVAVVRTPPKSPS), cis lock-in phosphorylated Thr231-Dmp tau (KVAVVRpT(5,5-dimethyl-Lproline)PKSPS), trans lock-in phosphorylated Thr231-Ala tau (P232A)(KVAV VRpTAPKSPS), and phosphorylated Thr231-Homoproline (pThr231-Pip) tau (CKKVAVVRpT(Pip)PKSPSSAK), which are synthesized by a commercial source.
NMR Spectrometry
Amide region of TOCSY spectra of tau-derived peptides (sequence KVAVVRpT231-X232-PKSPS) were used. Pro, Pip, Dmp, or Ala was incorporated into the sequence following pThr231. Two-dimensional 1H-1H TOCSY spectra (mixing time of 70 ms) were taken and the population of the cis isomer was determined by comparing peak volumes. Peaks used included the g, b, and a protons of pThr231 as seen from the amide proton in both the cis and trans states. cis and trans isomers were assigned by identifying characteristic through-space NOEs between Thr231 and Xaa232 protons in 1H-1H ROESY spectra.
Production and Purification of Antibodies
Rabbits were immunized with pThr231-Homoproline (pThr231-Pip) tau peptide that was coupled to KLH with N-terminal Cys. The resulting sera were purified with pThr231-Homoproline (pThr231-Pip) tau peptide. For the cis conformation-specific pT231-tau antibody, the resulting bound fraction was purified twice with cis pThr231-Dmp tau peptide to collect the bound fraction, followed by counterpurification with pThr231-Ala tau peptide. The unbound fraction was collected as the cis conformation-specific pThr231-Pro tau antibody. For the trans-specific pThr231-Pro tau antibody, the antibody was purified twice with wild-type pThr231-Pro tau peptide to collect the bound fraction, followed by counterpurification with pThr231-Dmp tau peptide. The unbound fraction was collected as the trans-specific pThr231-Pro tau antibody.
Human Brain Specimens
Brains from 11 patients with AD (Braak stage V and VI) (mean age ± standard error of the mean [SEM]: 78.4 ± 3.1 years old), 6 patients with MCI (Braak stage III and IV) (84.4 ± 5.6), and 9 healthy controls (Braak stage I and II) (78.0 ± 6.5) were used for the analyses. All AD subjects met the clinical, and neuropathological National Institute on Aging-Reagan Institute (NIA-RI) criteria, for AD. Our studies for human samples have been approved by our Institutional Review Board.
Transgenic Overexpression and Gene Knockout Mice
Tau-Tg mice (Ishihara et al., 1999) , Tau-Tg+Pin1-Tg mice, and Tau-Tg+Pin1 KO mice in C57BL/6 background were generated, as described (Lim et al., pT231-tau protein exists in the two completely distinct cis and trans conformations, as depicted in cartoons of the primary backbone structures. cis, but not trans, pT231-tau loses normal function and also gains toxic function. Pin1 prevents the accumulation of the pathogenic cis pT231-tau conformation in AD by converting it to the nonpathogenic trans form. Conformation-specific antibodies and/or vaccines against the pathogenic cis pT231-tau might be developed for the diagnosis and treatment of AD, especially during its early stages.
2008; Liou et al., 2003) . Tau knockout mice (Dawson et al., 2001) 
